Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GlaxoSmithKline (GSK) has announced the purchase of 166,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, is part of a larger effort that has seen GSK acquire over 6.4 million shares since September 2025. The purchased shares will be held as treasury shares, and the company now holds a total of 253,913,344 shares in treasury, with a total of 4,061,507,442 shares in issue. This move is likely to impact the company’s share value and could influence shareholder decisions regarding their investments.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The technical analysis supports a bullish outlook, though caution is advised due to nearing overbought indicators. Valuation is reasonable, providing a balanced investment opportunity.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 8,045,122
Technical Sentiment Signal: Buy
Current Market Cap: £65.11B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.